Structured evidence table for Phosphatidylserine Stress Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Phosphatidylserine Stress Randomized Trial | Failure to meet the recommended 7-9 hours of restful sleep per night is known to increase the risk of several health conditions, reason why regular and adequate sleep should be seen as a priority instead of an unnecessary commodity easily traded as required by the commitments of our busy lives. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Phosphatidylserine Stress Randomized Trial | While both the quantity and the quality of sleep can be largely improved with relatively straightforward practices dictated by good sleep hygiene, emerging research suggests that dietary and supplementation protocols focused on certain foods, nutrients, and biochemical compounds with sleep-promoting properties can act as subsidiary sleep aids in complementing these behavioral changes. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Phosphatidylserine Stress Randomized Trial | The scope of this narrative review is to summarize the available evidence on the potential benefits of selected nutraceuticals in the context of circadian rhythm and sleep disturbances, namely melatonin, magnesium, omega-3 fatty acids, tart cherry juice, kiwifruit, apigenin, valerian root, L-theanine, glycine, ashwagandha, myoinositol, Rhodiola rosea, and phosphatidylserine. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Phosphatidylserine Stress Randomized Trial | Humans spend approximately one third of their life asleep but, as counterintuitive as it may sound, sleep is far from being a quiet state of inactivity. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Phosphatidylserine Stress Randomized Trial | Given the lack of disease-modifying therapies for dementia, interventions that can stabilize or improve cognition at the MCI stage may substantially reduce future dementia incidence and associated healthcare costs. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
| Phosphatidylserine Stress Randomized Trial | Because reduced BDNF signaling is closely linked to synaptic dysfunction and memory decline in MCI, we measured BDNF expression in both in vitro and in vivo experiments and assessed downstream ERK/AKT/CREB signaling in the in vivo model. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
| Phosphatidylserine Stress Randomized Trial | Exposure to 0.3 mM HOfor 24 h markedly reduced cell viability andmRNA levels relative to those in the untreated control group, confirming the successful induction of oxidative cytotoxicity. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
| Phosphatidylserine Stress Randomized Trial | 1 2 3 4 5 6 Mild cognitive impairment (MCI) refers to more than normal cognitive decline with age, yet insufficient to warrant a diagnosis of dementia []. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
Source documents